Skip to main content
SpringerLink
Log in

Neoadjuvante Therapie des operablen NSCLC mit Immun-Checkpoint-Inhibitoren

Pilotstudie zeigt gutes Tumoransprechen und wenige Nebenwirkungen

Neoadjuvant treatment of operable NSCLC with immune checkpoint inhibitors

Pilot study shows good tumor response and few side effects

  • Journal Club
  • Published:
Der Pneumologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O’Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375(19):1823–1833

    Article  PubMed  CAS  Google Scholar 

  2. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378(21):1976–1986

    Article  PubMed  CAS  Google Scholar 

  3. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247

    Article  PubMed  CAS  Google Scholar 

  4. Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F (2018) Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 6(1):39. https://doi.org/10.1186/s40425-018-0349-3

    Article  PubMed  PubMed Central  Google Scholar 

  5. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell R, Seymour L, Spiro SG, Rolland E, Fossati R, Aubert D, Ding K, Waller D, Le Chevalier T, Collaborative Group (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559

    Article  PubMed  Google Scholar 

  6. Samson P, Crabtree TD, Robinson CG, Morgensztern D, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers B, Puri V (2017) Defining the ideal time interval between planned induction therapy and surgery for stage IIIA non-small cell lung cancer. Ann Thorac Surg 103(4):1070–1075

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Herz- und Thoraxchirurgie, Universitätsklinikum Magdeburg, Leipziger Straße 44, 39120, Magdeburg, Deutschland

    T. Walles FETCS

Authors
  1. T. Walles FETCS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Walles FETCS.

Ethics declarations

Interessenkonflikt

T. Walles gibt an, dass kein Interessenkonflikt besteht.

Additional information

Redaktion

J. Schreiber, Magdeburg

P. Zabel, Lübeck/Borstel

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Walles, T. Neoadjuvante Therapie des operablen NSCLC mit Immun-Checkpoint-Inhibitoren. Pneumologe 15, 349–350 (2018). https://doi.org/10.1007/s10405-018-0200-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10405-018-0200-z

Search

Navigation